Transcenta Holding Limited 6628.HK Stock
Transcenta Holding Limited Price Chart
Transcenta Holding Limited 6628.HK Financial and Trading Overview
Transcenta Holding Limited stock price | 1.2 HKD |
Previous Close | 5.28 HKD |
Open | 5.28 HKD |
Bid | 5.3 HKD x N/A |
Ask | 5.38 HKD x N/A |
Day's Range | 5.24 - 5.72 HKD |
52 Week Range | 2.12 - 6.2 HKD |
Volume | 37.5K HKD |
Avg. Volume | 82.03K HKD |
Market Cap | 2.26B HKD |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.23 HKD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.96 HKD |
6628.HK Valuation Measures
Enterprise Value | 1.67B HKD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 22.132957 |
Price/Book (mrq) | 1.4665191 |
Enterprise Value/Revenue | 16.382 |
Enterprise Value/EBITDA | -4.236 |
Trading Information
Transcenta Holding Limited Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | 10.00% |
S&P500 52-Week Change | 20.43% |
52 Week High | 6.2 HKD |
52 Week Low | 2.12 HKD |
50-Day Moving Average | 4.46 HKD |
200-Day Moving Average | 3.52 HKD |
6628.HK Share Statistics
Avg. Volume (3 month) | 82.03K HKD |
Avg. Daily Volume (10-Days) | 53.15K HKD |
Shares Outstanding | 425.5M |
Float | 229.95M |
Short Ratio | N/A |
% Held by Insiders | 21.59% |
% Held by Institutions | 29.46% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -434.12% |
Gross Margin | 19.52% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -11.81% |
Return on Equity (ttm) | -23.65% |
Income Statement
Revenue (ttm) | 101.89M HKD |
Revenue Per Share (ttm) | 0.24 HKD |
Quarterly Revenue Growth (yoy) | 240.20% |
Gross Profit (ttm) | 19.89M HKD |
EBITDA | -394028000 HKD |
Net Income Avi to Common (ttm) | -406744992 HKD |
Diluted EPS (ttm) | -1.05 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 895.45M HKD |
Total Cash Per Share (mrq) | 2.2 HKD |
Total Debt (mrq) | 411.46M HKD |
Total Debt/Equity (mrq) | 27.92 HKD |
Current Ratio (mrq) | 1.92 |
Book Value Per Share (mrq) | 3.614 |
Cash Flow Statement
Operating Cash Flow (ttm) | -295807008 HKD |
Levered Free Cash Flow (ttm) | -213746624 HKD |
Profile of Transcenta Holding Limited
Country | Hong Kong |
State | N/A |
City | Suzhou |
Address | B6-501, 218 Xinghu Street |
ZIP | 215123 |
Phone | 86 21 6237 0929 |
Website | https://www.transcenta.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 320 |
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People's Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric cancer and is under Phase II clinical trial; TST005, a PD-L1/TGF-ß bi-functional antibody candidate which is under Phase Ia clinical trial for solid tumors, including certain lung cancers; TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing;TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST003, an antibody candidate targeting a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells with mesenchymal phenotype; TST006, a bi-specific claudin 18.2/PD-L1 antibody; TST008, a tri-functional antibody combining a MASP2 antibody fused with a truncated transmembrane activator and CAML interactor protein; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors and is under Phase Ib/IIa clinical trials; and MSB2311, A humanized PD-L1 mAb Candidate for solid tumors and is under Phase Ib/IIa clinical trials. It has collaboration agreements with Eli Lilly and Company, Alebund Pharmaceuticals, and Merck. The company was formerly known as MabSpace International Limited and changed its name to Transcenta Holding Limited in June 2019. Transcenta Holding Limited was incorporated in 2010 and is headquartered in Suzhou, the People's Republic of China.
Q&A For Transcenta Holding Limited Stock
What is a current 6628.HK stock price?
Transcenta Holding Limited 6628.HK stock price today per share is 1.2 HKD.
How to purchase Transcenta Holding Limited stock?
You can buy 6628.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Transcenta Holding Limited?
The stock symbol or ticker of Transcenta Holding Limited is 6628.HK.
Which industry does the Transcenta Holding Limited company belong to?
The Transcenta Holding Limited industry is Biotechnology.
How many shares does Transcenta Holding Limited have in circulation?
The max supply of Transcenta Holding Limited shares is 435.2M.
What is Transcenta Holding Limited Price to Earnings Ratio (PE Ratio)?
Transcenta Holding Limited PE Ratio is now.
What was Transcenta Holding Limited earnings per share over the trailing 12 months (TTM)?
Transcenta Holding Limited EPS is -1.23 HKD over the trailing 12 months.
Which sector does the Transcenta Holding Limited company belong to?
The Transcenta Holding Limited sector is Healthcare.